Skip to Content

Demant A/S DEMANT

Morningstar Rating
DKK 319.00 −12.60 (3.80%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Demant Sees Strong Recovery in Hearing but Continuing Weakness in Communications

Demant benefits from favourable trends, including an ageing population, increasing noise pollution, fairly low penetration rates in the developed world, and virtually untapped patient populations in emerging markets such as China where Demant acquired the retail chain ShengWang in June 2022. Demant's broad product offerings should allow the company to capitalize on these trends, while its strong brand and superior technological know-how should yield market share gains. After selling its implant business, Demant is in a better position to focus its efforts and maintain its top-tier positioning in the market.

Price vs Fair Value

DEMANT is trading at a 18% premium.
Price
DKK 331.60
Fair Value
DKK 959.00
Uncertainty
Medium
1-Star Price
DKK 291.00
5-Star Price
DKK 256.00
Economic Moat
Xqsmvms
Capital Allocation
Qblhrdyc

Bulls Say, Bears Say

Bulls

Approximately 16% of the world's population suffers from mild to severe hearing loss, and this is expected to grow to 20% during the next decade. Even in developed countries, hearing aid penetration rates only reach 20% on average.

Bears

The communications segment is struggling in both the gaming and professional lines.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DEMANT is a good fit for your portfolio.

Trading Information

Previous Close Price
DKK 331.60
Day Range
DKK 318.80334.20
52-Week Range
DKK 247.90373.50
Bid/Ask
DKK 318.80 / DKK 319.20
Market Cap
DKK 70.53 Bil
Volume/Avg
303,564 / 295,195

Key Statistics

Price/Earnings (Normalized)
29.33
Price/Sales
3.30
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
1.15%

Company Profile

Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and audio diagnostic equipment. More than 80% of the company's sales come from North America and Europe.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Growth
Total Number of Employees
21,623

Competitors

Valuation

Metric
DEMANT
GN
SOON
Price/Earnings (Normalized)
29.3332.4621.47
Price/Book Value
7.912.837.23
Price/Sales
3.301.434.20
Price/Cash Flow
17.1011.7919.86
Price/Earnings
DEMANT
GN
SOON

Financial Strength

Metric
DEMANT
GN
SOON
Quick Ratio
0.840.480.76
Current Ratio
1.370.651.29
Interest Coverage
6.911.8629.18
Quick Ratio
DEMANT
GN
SOON

Profitability

Metric
DEMANT
GN
SOON
Return on Assets (Normalized)
8.40%0.30%11.96%
Return on Equity (Normalized)
28.27%1.10%30.61%
Return on Invested Capital (Normalized)
12.19%1.28%22.85%
Return on Assets
DEMANT
GN
SOON
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesBnglsyvGbsdy$189.3 Bil
SYK
Stryker CorpHczykmsbwJbfm$130.1 Bil
MDT
Medtronic PLCBlcnjyvyTkhgj$109.3 Bil
BSX
Boston Scientific CorpCylccmsGymnhy$100.9 Bil
EW
Edwards Lifesciences CorpZhvgtgcgTqgqz$54.3 Bil
DXCM
DexCom IncLrcrtmmwFvy$54.1 Bil
ZBH
Zimmer Biomet Holdings IncGvfpdnbfrPpq$25.6 Bil
ALGN
Align Technology IncRxrglxqbzDvcrm$24.7 Bil
PHG
Koninklijke Philips NV ADRKzndcfxgPhhgvf$18.8 Bil
PODD
Insulet CorpWczxwsghCmmgqjh$12.3 Bil

Sponsor Center